Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abrocitinib Phase 2b in moderate-to-severe atopic dermatitis
NCT02780167Phase 2Completed
- Sponsor
- Pfizer
- Start
- Apr 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of abrocitinib in atopic dermatitis (AD) (5 arms), sponsored by Pfizer. Primary endpoint: Investigator's Global Assessment Response at 12 weeks. Started Apr 2016; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02780167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02780167.